Marc Salzberg
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Lung Cancer Treatments and Mutations, Glycosylation and Glycoproteins Research, HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors(2007)851 cited
- → Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer(2005)468 cited
- → Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects(2013)376 cited
- → Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer(2003)172 cited
- → A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer(2013)101 cited
- → Combining Capecitabine and Gemcitabine in Patients With Advanced Pancreatic Carcinoma: A Phase I/II Trial(2002)95 cited
- → A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas(2016)71 cited
- → Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis(2007)66 cited
- → A Pilot Study with Very Low-Intensity, Intermediate-Frequency Electric Fields in Patients with Locally Advanced and/or Metastatic Solid Tumors(2008)66 cited
- → Current Concepts of Treatment Strategies in Advanced or Recurrent Ovarian Cancer(2005)64 cited